内科理论与实践2011，Vol.6Issue(3)：192-195,4.
文拉法辛缓释剂治疗抑郁症伴发焦虑的临床疗效
Clinical study of veniafaxine extended release capsule in treatment of depression associated with anxiety
摘要
Abstract
Objective To evaluate the efficacy and safety of venlafaxine extended release capsule in the treatment of depression associated with anxiety. Methods A randomized, double-blind, and double-dummy clinical trial was performed to compare the efficacy and safety of venlafaxine extended release capsule with fluoxetine as the control. One hundred and eleven depression patients associated with anxiety [Hamilton rating scale for depression (HAMD) ≥ 18 and Hamilton anxiety scale (HAMA) ≥ 14] were enrolled, 60 patients was randomized to study group and 51 patients to control group. Patients in study group were given venlafaxine extended release capsule 75 mg/d, and fluoxetine 20 mg/d was given to patients in control group. The treatment duration was 6 week. HAMA and HAMD were measured at baseline and week 1, 2, 4 and 6 of study. Safety was assayed by treatment emergent symptom scale (TESS) and laboratory and physical examinations. Results After 6 weeks treatment,the clinical cure rate of depression associated with anxiety in venlafaxine group was 35％ and the response rate was 82％, and the clinical cure rate and response rate of fluoxetine group were 31％and 73％, respectively (P 〉0.05). However, venlafaxine had a more rapid onset of action. The adverse effect of venlafaxine was mild. Conclusions Venlafaxine extended release capsule is an effective and safe medicine for the treatment of depression associated with anxiety, and venlafaxine has a more rapid onset of action.关键词
文拉法辛/氟西汀/抑郁症伴发焦虑/有效性Key words
Venlafaxine/ Fluoxetine/ Depression/ Anxiety/ Efficacy分类
医药卫生引用本文复制引用
姚军,吴文源..文拉法辛缓释剂治疗抑郁症伴发焦虑的临床疗效[J].内科理论与实践,2011,6(3):192-195,4.基金项目
文拉法辛缓释剂中国注册试验(方案号:PRC-VENXR001) （方案号:PRC-VENXR001）
